How to Buy Lineage Cell Therapeutics Stock
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally.
Lineage Cell Therapeutics stock last closed at $0.84, down 4.02% from the previous day, and has decreased 38.07% in one year. It has underperformed other stocks in the Biotechnology industry by 0.28 percentage points. Lineage Cell Therapeutics stock is currently +9.14% from its 52-week low of $0.77, and -48.07% from its 52-week high of $1.61.
At the moment, there are 188.84M LCTX shares outstanding. The market capitalization of LCTX is $157.87M. In the past 24 hours, 375,879 LCTX shares were traded.
How to Buy Lineage Cell Therapeutics Stock
Wondering how to invest in Lineage Cell Therapeutics stock? Here's how.
- Choose where to buy Lineage Cell Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you figure out where to buy Lineage Cell Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit money your brokerage account: Choose your payment method and add your details.
- Analyze Lineage Cell Therapeutics stock: The Lineage Cell Therapeutics ticker symbol is LCTX. Is Lineage Cell Therapeutics stock a good investment? Should you buy shares of LCTX? How do LCTX's underlying business fundamentals look? Do top analysts think Lineage Cell Therapeutics is a good buy? Why has LCTX's stock price moved recently? (Hint: Our stock analysis website can help you understand if LCTX is a good stock to buy).
- Place your LCTX trade: Decide if you will purchase LCTX shares at the current market price or use a limit order to buy LCTX shares at a particular price.
- Monitor your LCTX position: Create a watchlist to important notifications about your investment in Lineage Cell Therapeutics shares.
Step 1: Choose where to buy Lineage Cell Therapeutics stock
You need an online brokerage account to access the NYSEMKT market and buy LCTX shares.
Our preferred brokerage: eToro
Based on our research, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Real Estate, New York to Hong Kong — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal information so you are able to buy LCTX stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start a new brokerage account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've filled out your info on the best stock market app, you need to deposit funds:
Check out this video walkthrough to see the process of transferring funds into your new investment account.
Step 4: Analyze Lineage Cell Therapeutics stock
Once you have figured out the best place to buy Lineage Cell Therapeutics stock, it's critical to research their stock prior to investing, so you truly comprehend the risk as well as the upside.
Lineage Cell Therapeutics shares at a glance
Fundamentals of Lineage Cell Therapeutics
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on LCTX's stock page.
Is LCTX stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge LCTX's true value.
Using relative valuations methods:
- LCTX could be undervalued based on its P/B ratio of 2.31x, relative to Biotechnology industry P/B ratio of 6.22x
You can access additional valuation research on LCTX's stock here.
Is LCTX a healthy company?
Passed Health Checks:
- LCTX has cash burn of 22333000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the LCTX balance sheet.
- LCTX has $38.50M in cash and short term investments. This is sufficient to cover its annual cash burn of $22.33M.
- There are more short-term assets than long-term liabilities on the LCTX balance sheet.
Failed Health Checks:
- Total LCTX debt is higher than 5 years ago, relative to shareholder equity.
- LCTX profit margin has gone down from -209.3% to -391% in the past year.
- LCTX has a relatively high debt to equity ratio of 0.53.
Is it a good time to buy Lineage Cell Therapeutics stock, according to analysts?
Out of 2 Equities analysts who research LCTX, the consensus analyst rating on LCTX is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Lineage Cell Therapeutics stock forecast page.
LCTX Technicals
Is LCTX Growing Revenue?
Last year, LCTX revenue was $6.19M. In the last five year, LCTX's revenue has gone up by 12.41% per year. This was slower than the Biotechnology industry average of 58.62%.
Learn more about LCTX's earnings and revenue performance here.
What are LCTX executives and large shareholders up to?
In the past year, insiders at LCTX have bought more shares than they have sold.
Jill Ann Howe, Chief Financial Officer of LCTX, was the latest LCTX insider to buy. They bought $9,345.00 worth of LCTX shares on Aug 16, 2024.
Research more about who owns LCTX shares here.
Can I rely on LCTX as an income stream?
No, Lineage Cell Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about LCTX?
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your LCTX trade
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount, use a limit order.
Hit the Open Trade button and your broker will place your order.
If you want more info about investing in stocks on eToro, click the helpful video below:
Step 6: Monitor your LCTX position
Now that you own some LCTX shares, you'll want to keep up with your new investment.
Start a watchlist to get notified of important updates regarding your LCTX stock.
LCTX Feed
How to Buy Stock in Lineage Cell Therapeutics
To reiterate, here are the 6 steps to buy stock in Lineage Cell Therapeutics:
- Choose where to buy Lineage Cell Therapeutics stock
- Create your brokerage account
- Deposit money your brokerage account
- Analyze Lineage Cell Therapeutics stock
- Place your LCTX trade
- Monitor your LCTX position
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Lineage Cell Therapeutics, add LCTX to your watchlist by clicking the button below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.